This from last edison report WH.....
Valuation: Unchanged at $192m, $9.24 per ADR Our valuation is unchanged at $192m, which is equal to ($9.24 per ADR) on an undiluted basis or $6.37/ADR after accounting for dilution from options, warrants and convertible notes. Guidance is that the cash balance of $12.6m at 31 December will be sufficient to fund operations through Q1 CY18, excluding any milestone payments from partners Novartis and GSK. Milestone revenue (we model ~$7m in FY18) would extend the cash runway.
These gsk and novartis trials seem to have been going on forever.....
- Forums
- ASX - By Stock
- IMP321 and solid tumours
This from last edison report WH..... Valuation: Unchanged at...
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
38.0¢ |
Change
0.010(2.70%) |
Mkt cap ! $451.7M |
Open | High | Low | Value | Volume |
36.5¢ | 38.3¢ | 36.5¢ | $219.2K | 583.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 27027 | 37.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
38.5¢ | 58000 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 27027 | 0.370 |
6 | 71996 | 0.365 |
9 | 482702 | 0.360 |
4 | 38816 | 0.355 |
7 | 35876 | 0.350 |
Price($) | Vol. | No. |
---|---|---|
0.385 | 58000 | 3 |
0.390 | 85258 | 5 |
0.395 | 30000 | 1 |
0.400 | 80622 | 7 |
0.405 | 108286 | 4 |
Last trade - 16.10pm 29/03/2024 (20 minute delay) ? |
|
|||||
Last
38.0¢ |
  |
Change
0.010 ( 2.43 %) |
|||
Open | High | Low | Volume | ||
37.0¢ | 38.0¢ | 37.0¢ | 151143 | ||
Last updated 15.59pm 29/03/2024 ? |
Featured News
IMM (ASX) Chart |